background
base
clinic
represent
diseas
symptom
multipl
sclerosi
mscl
patient
divid
two
major
subtyp
relaps
remit
rr
mscl
primari
progress
pp
mscl
proteom
analysi
cerebrospin
fluid
csf
detect
number
protein
elev
mscl
patient
specif
aim
differenti
pp
rr
subtyp
mscl
compar
csf
protein
methodologyprincip
find
csf
sampl
n
handl
accord
protocol
quantit
mass
spectrometri
measur
report
previous
comparison
pp
mscl
versu
rr
mscl
observ
number
differenti
abund
protein
protein
vitamin
dbind
protein
protein
three
time
less
abund
pp
mscl
compar
rr
mscl
vitamin
dbind
protein
detect
rr
mscl
sampl
two
protein
valid
independ
techniqu
western
blot
elisa
differenti
abund
comparison
mscl
type
multipl
sclerosi
mscl
divid
two
major
subtyp
base
clinic
represent
diseas
symptom
patient
patient
classifi
relaps
remit
rr
mscl
subtyp
diseas
relaps
follow
period
remiss
mscl
patient
diagnos
primari
progress
pp
subtyp
even
within
singl
larg
dutch
mscl
pedigre
patient
similar
genet
background
percentag
patient
pp
phenotyp
remain
definit
pp
patient
diseas
progress
character
progress
cours
without
relaps
remiss
onset
diseas
pp
patient
tend
lower
inflammatori
lesion
activ
immunolog
genet
explan
identifi
yet
scarc
compar
neuropatholog
studi
show
larg
overlap
lesion
patholog
indic
less
inflammatori
activ
pp
still
substanti
axon
damag
gener
pictur
relaps
onset
pp
form
share
substanti
characterist
word
remain
challeng
identifi
biolog
paramet
determin
pp
diseas
cours
although
proteom
analysi
activ
multipl
sclerosi
lesion
may
straightforward
approach
studi
process
involv
mscl
diseas
pathway
difficult
perform
live
individu
case
patholog
diseas
investig
postmortem
materi
quit
frequent
repres
endstag
diseas
studi
csf
taken
diseas
appear
good
altern
csf
close
contact
cn
parenchyma
collect
product
inflammatori
neurodegen
process
mscl
activ
proteom
analysi
csf
detect
number
protein
elev
mscl
patient
addit
differenti
abund
protein
identifi
proteom
apolipoprotein
chromogranin
valid
techniqu
studi
ad
addit
data
elev
immunoglobulin
express
mscl
csf
well
increas
level
apolipoprotein
e
yet
current
report
proteom
csf
studi
mscl
patient
either
singl
subtyp
mscl
patient
combin
group
subtyp
mscl
studi
whilst
differ
subtyp
mscl
remain
unexplor
rr
mscl
pp
mscl
differ
term
diseas
cours
diseas
progress
also
therapeut
consequ
henc
probabl
also
differ
biolog
patholog
level
could
determin
use
elucid
biolog
patholog
diseas
type
current
studi
specif
aim
differenti
mscl
patient
healthi
control
subtyp
mscl
compar
csf
protein
peptid
subsequ
identifi
biomark
protein
peptid
discuss
relat
differ
patholog
process
observ
rr
mscl
pp
mscl
csf
sampl
mscl
patient
divid
two
group
rr
mscl
pp
mscl
collect
untreat
patient
undergo
routin
diagnost
procedur
experienc
neurologist
rqh
match
presenc
absenc
oligoclon
band
healthi
control
csf
sampl
taken
patient
receiv
spinal
anesthesia
prior
nonneurolog
minor
surgic
intervent
knee
hip
replac
groin
ruptur
achil
tendon
ruptur
sampl
handl
exactli
way
sampl
use
procedur
previous
report
brief
immedi
sampl
csf
sampl
centrifug
discard
cell
cellular
element
total
protein
concentr
albumin
concentr
determin
number
oligoclon
band
intrathec
cell
count
also
report
remain
volum
sampl
aliquot
store
remain
sampl
prepar
studi
extra
freezethaw
cycl
allow
csf
sampl
handl
accord
protocol
quantit
maldifticr
ms
measur
report
previous
consist
blind
experi
sampl
digest
trypsin
subsequ
measur
maldifticr
apex
iv
qe
tesla
maldifticr
mass
spectromet
bruker
dalton
usa
calibr
mean
omnipres
albumin
peak
analysi
matrix
gener
univari
analysi
pvalu
determin
everi
peak
posit
use
statist
analysi
two
group
compar
time
total
three
individu
comparison
group
differenti
abund
peak
comparison
consid
identif
purpos
fold
increas
everi
identifi
peptid
comparison
determin
confirm
differenti
abund
group
assess
statist
background
mean
permut
seri
scrambl
sampl
comparison
use
defin
cutoff
number
determin
statist
signific
differ
group
permut
procedur
sampl
randomli
assign
new
group
number
scrambl
sampl
group
composit
prior
perform
univari
analysi
determin
pvalu
peak
posit
method
number
peak
assign
pvalu
chanc
determin
iter
repetit
procedur
allow
statist
relev
mean
standard
deviat
could
taken
realist
background
valu
normal
distribut
data
differenti
abund
peptid
identifi
nanolcesiorbitrap
ms
measur
carri
ultim
nano
lc
system
dionex
germer
germani
onlin
coupl
hybrid
linear
ion
traporbitrap
ms
ltq
orbitrap
xl
thermo
fisher
scientif
germani
five
ml
digest
load
trap
column
pepmap
mm
id
mm
mm
particl
size
pore
size
dionex
netherland
desalt
minut
use
flow
rate
mlmin
tfa
trap
column
switch
onlin
analyt
column
pepmap
mm
id
mm
mm
particl
pore
size
dionex
netherland
peptid
elut
follow
binari
gradient
solvent
b
min
solvent
b
minut
solvent
consist
acetonitril
formic
water
solvent
b
consist
acetonitril
formic
acid
water
column
flow
rate
set
nl
min
ms
detect
data
depend
acquisit
method
use
high
resolut
survey
scan
th
perform
orbitrap
valu
target
automat
gain
control
agc
resolut
mz
lock
mass
set
u
proton
si
ch
base
survey
scan
intens
ion
consecut
isol
agc
target
set
ion
fragment
collisionactiv
dissoci
cad
appli
normal
collis
energi
linear
ion
trap
precursor
select
msm
exclud
msm
spectra
minut
msm
identif
obtain
use
biowork
peak
pick
extractmsn
default
set
softwar
packag
thermo
fisher
scientif
germani
sequest
featur
use
minimum
xc
score
reliabl
identif
singl
doubl
tripl
charg
ion
respect
uniprotdatabas
version
human
taxonomi
entri
carboxymethyl
cystein
u
fix
oxid
methionin
u
variabl
modif
tryptic
cleavag
consid
number
allow
miss
cleavag
mass
toler
precursor
ion
ppm
fragment
ion
da
cutoff
mass
differ
theoret
mass
identifi
peptid
set
ppm
contamin
csf
serum
plasma
possibl
issu
csf
peptid
profil
one
sampl
contamin
serum
plasma
comparison
csf
peptid
profil
inevit
skew
higher
total
protein
concentr
serum
plasma
prevent
inclus
contamin
csf
sampl
studi
csf
sampl
check
specif
blood
contamin
hemoglobin
peptid
could
identifi
nanolcesiorbitrap
c
column
suffici
high
confid
score
mass
peak
part
hemoglobin
gamma
signal
nois
higher
maldifticr
measur
sampl
discard
analysi
due
plasmaserum
contamin
anoth
blood
specif
protein
apolipoprotein
check
way
possibl
blood
contamin
two
protein
found
differenti
abund
peptid
perform
valid
experi
done
commerci
avail
elisa
vitamin
dbind
protein
western
blot
protein
use
valid
cohort
patient
consist
rr
mscl
pp
mscl
sampl
sampl
valid
cohort
demograph
clinic
compar
origin
cohort
patient
averag
edss
rr
mscl
group
standard
deviat
bracket
averag
edss
pp
mscl
group
diseas
durat
presenceabs
oligoclon
igg
band
male
femal
ratio
similar
origin
cohort
pvalu
use
ttest
compar
group
addit
also
measur
origin
sampl
use
elisa
western
blot
first
protein
vitamin
dbind
protein
perform
commerci
avail
elisa
immundiagnostik
germani
accord
manufactur
specif
second
protein
differenti
abund
mscl
type
perform
twostep
western
blot
use
goat
antibodi
primari
antibodi
antigoat
antibodi
secondari
antibodi
sigma
aldrich
unit
state
protein
transfer
check
ponceau
stain
quantit
assess
gel
band
photoluminesc
perform
use
imag
j
freeli
avail
wwwrsbinfonihgovij
total
csf
sampl
use
mass
spectrometri
analysi
twenti
sampl
twenti
addit
sampl
use
valid
experi
sampl
analyz
mass
spectrometri
test
neg
serumplasma
contamin
maldifticr
measur
howev
three
sampl
abl
identifi
hemoglobin
peptid
suffici
high
xc
score
confid
identif
use
nanolcesiorbitrap
measur
three
sampl
pp
mscl
rr
mscl
subsequ
exclud
analysi
analysi
matrix
use
profil
differ
peptid
profil
three
group
consist
therefor
csf
sampl
tabl
supplementari
inform
sampl
file
maldifticr
spectra
load
peptrix
tm
softwar
packag
tag
group
number
pp
mscl
rr
mscl
control
respect
calibr
use
five
omnipres
albumin
peak
follow
gener
analysi
matrix
intens
peak
everi
sampl
record
detect
peak
supplementari
inform
matrix
file
use
wilcoxonmannwhitney
test
compar
group
pairwis
comparison
mscl
type
result
peak
mass
pvalu
scrambl
sampl
group
number
background
peak
determin
number
differenti
abund
peptid
peak
comparison
two
mscl
type
around
level
number
background
peak
indic
differ
two
group
appear
nonexist
least
background
level
howev
protein
identifi
low
pvalu
comparison
substanti
interest
mscl
context
total
peptid
peak
pvalu
observ
comparison
pp
mscl
versu
control
comparison
rr
mscl
versu
control
peak
mass
pvalu
lower
seventeen
peak
mass
present
comparison
identif
differenti
abund
peptid
perform
measur
sampl
use
nanolcesiorbitrap
due
prefraction
nanolc
far
peak
mass
identif
gener
esiorbitrap
peak
mass
analysi
matrix
gener
quantit
maldifticr
although
mani
identifi
peptid
correspond
peak
mass
analysi
matrix
abl
identifi
number
differenti
abund
peptid
three
comparison
full
list
includ
charg
state
sequenc
coverag
found
supplementari
materi
supplementari
inform
mass
spectrometri
file
differenti
abund
peptid
mass
observ
use
maldifticr
mass
spectrometri
comparison
pp
mscl
versu
control
abl
identifi
peptid
supplementari
inform
tabl
peptid
includ
sever
peptid
ig
ig
kappa
anoth
differenti
abund
peptid
identifi
part
apolipoprotein
previous
shown
elev
intrathec
mscl
patient
comparison
rr
mscl
versu
control
abl
identifi
differenti
abund
peptid
mass
case
comparison
pp
mscl
versu
rr
mscl
show
limit
number
differenti
abund
peptid
peak
peak
identifi
notabl
protein
tabl
particular
protein
three
time
less
abund
pp
mscl
compar
rr
mscl
anoth
interest
differenti
abund
protein
vitamin
dbind
protein
detect
mass
spectrometri
pp
mscl
sampl
detect
rr
mscl
sampl
protein
serin
threonin
kinas
nlk
sodium
leak
channel
nonselect
protein
abund
pp
mscl
rr
mscl
although
latter
protein
differ
small
fold
increas
main
interest
focus
differ
two
mscl
type
select
two
differenti
abund
protein
comparison
valid
purpos
use
pp
mscl
rr
mscl
sampl
measur
mass
spectrometri
addit
pp
mscl
rr
mscl
sampl
independ
patient
valid
elisa
show
concentr
vitamin
dbind
protein
significantli
lower
ttest
pp
mscl
group
compar
rr
mscl
group
sampl
also
measur
maldifticr
ms
tabl
similar
result
observ
new
clinic
demograph
compar
valid
sampl
tabl
western
blot
quantit
assess
gel
band
show
protein
inde
less
abund
pp
mscl
rr
mscl
ttest
photoluminesc
readout
valu
origin
sampl
set
show
pvalu
compar
rr
pp
mscl
sampl
tabl
comparison
valid
sampl
also
show
pvalu
indic
signific
differenti
abund
two
mscl
diseas
type
tabl
order
place
identifi
protein
biolog
context
upload
ingenu
pathway
analysi
servic
ingenu
system
network
analysi
six
seven
differenti
abund
protein
place
network
relat
neurolog
diseas
figur
main
find
compar
studi
observ
proteom
profil
csf
pp
vs
rr
mscl
patient
overlap
larg
extent
line
lack
clearcut
differ
two
major
clinic
mscl
subgroup
genet
immunolog
neuropatholog
level
interestingli
approach
use
sensit
stateof
art
mass
spectrometri
techniqu
led
identif
distinct
csf
protein
biolog
function
appear
direct
interest
mscl
patholog
two
protein
valid
techniqu
well
valid
sampl
set
lack
statist
power
due
low
number
biolog
sampl
avail
studi
led
less
ideal
statist
analysi
mean
report
pvalu
may
directli
associ
diseas
patholog
howev
report
unvalid
protein
signific
biolog
interest
among
sever
immunoglobulin
protein
previous
report
elev
csf
mscl
patient
number
peak
low
pvalu
comparison
two
mscl
type
lower
number
background
peak
strong
indic
even
though
may
peptid
protein
differenti
abund
comparison
overal
differ
two
diseas
type
appear
undetect
mean
univari
analysi
one
peptid
protein
three
time
less
abund
pp
mscl
also
observ
lower
incid
group
tabl
protein
ligand
multipl
notch
receptor
involv
mediat
notch
signal
influenc
neuron
function
develop
notch
signal
pathway
long
known
influenc
cell
fate
develop
nervou
system
found
highli
express
hypertroph
astrocyt
within
around
activ
mscl
plaqu
lack
remyelin
contrast
neglig
express
remyelin
lesion
suggest
involv
notch
pathway
remyelin
mscl
later
linkag
equilibrium
screen
implic
number
gene
includ
gene
suscept
gene
mscl
larg
conting
european
also
suggest
therapeut
potenti
treatment
cell
mediat
diseas
due
abil
deliv
indirect
neg
signal
cell
vivo
addit
anim
model
shown
elev
express
notch
express
appear
limit
factor
remyelin
anim
model
studi
report
quantit
differ
express
cell
slow
rapidli
remyelin
lesion
indic
notchjag
signal
ratelimit
determin
remyelin
rodent
model
demyelin
addit
immunohistochemistri
experi
shown
constitu
notch
pathway
express
remyelin
anim
model
tcelland
antibodymedi
cn
demyelin
howev
network
studi
base
quantit
express
level
gene
one
hundr
individu
identifi
new
therapeut
target
whose
differenti
behavior
mscl
network
modifi
immunomodulatori
therapi
illustr
network
analysi
predict
therapeut
target
immun
intervent
identifi
immunomodulatori
properti
make
new
therapeut
target
mscl
autoimmun
diseas
identifi
peptid
vitamin
dbind
protein
observ
pp
mscl
sampl
small
peak
peptid
detect
rr
mscl
sampl
impair
vitamin
homeostasi
wide
implic
mscl
year
vitamin
directli
indirectli
regul
differenti
activ
tlymphocyt
prevent
develop
autoimmun
process
may
involv
mscl
consid
geograph
incid
mscl
indic
increas
mscl
decreas
sunlight
exposur
vitamin
produc
skin
solar
uv
irradi
high
serum
level
report
correl
reduc
risk
mscl
protect
role
vitamin
suggest
principl
circul
metabolit
vitamin
bound
protein
approxim
bound
vitamin
dbind
protein
recent
csf
proteom
studi
show
serum
level
vitamin
dbind
protein
decreas
significantli
rr
mscl
patient
compar
neurolog
disord
result
indic
differenti
abund
differ
mscl
subtyp
control
two
diseas
type
vari
significantli
csf
level
vitamin
dbind
protein
rr
mscl
show
higher
abund
sinc
neuroprotect
function
suggest
vitamin
may
pp
mscl
neuroprotect
pathway
least
partial
defici
result
significantli
disabl
diseas
manifest
howev
forgotten
vitamin
dbind
protein
pleiotrop
function
beyond
vitamin
metabol
significantli
enhanc
chemotact
respons
complement
fragment
substanti
stimulatori
effect
macrophag
light
increasingli
recogn
role
innat
immun
progress
phase
ms
pathogenesi
vitamin
dbind
protein
appear
interest
candid
mediat
identif
peptid
differenti
abund
comparison
mscl
diseas
type
somewhat
mislead
anoth
seven
peptid
protein
identifi
among
peak
mass
analysi
matrix
high
pvalu
comparison
pp
rr
mscl
like
low
pvalu
peptid
reflect
high
abund
protein
variat
suggest
low
pvalu
like
fals
posit
contrast
protein
differenti
abund
comparison
either
identifi
singl
peptid
list
tabl
multipl
peptid
low
pvalu
identif
peptid
albumin
serotransferrin
stand
tabl
differenti
abund
peptid
protein
identif
essenti
correct
must
note
identifi
albumin
peptid
identifi
serotransferrin
peptid
pvalu
mean
valu
peptid
two
particular
protein
like
due
reason
larg
abund
differ
two
protein
comparison
differenti
abund
protein
identifi
found
small
number
peptid
low
pvalu
singl
peptid
low
pvalu
protein
observ
peptid
nonsignific
pvalu
except
bromodomain
adjac
zinc
finger
domain
protein
rho
gtpaseactiv
protein
protein
anoth
peptid
identifi
high
pvalu
indic
protein
like
differenti
abund
peptid
low
pvalu
protein
also
character
low
fold
increas
make
less
interest
independ
immunoassay
followup
healthi
state
csf
control
group
intrathec
inflammatori
respons
expect
group
therefor
clear
differ
immunoglobulin
abund
comparison
mscl
diseas
type
explain
two
comparison
mscl
type
control
group
sever
protein
present
comparison
exampl
ig
chain
c
region
apolipoprotein
apolipoprotein
previous
implic
mscl
proteom
studi
shown
apolipoprotein
e
abund
elev
csf
mscl
patient
compar
control
central
nervou
system
apolipoprotein
lipocalin
mainli
express
glia
also
neuron
protein
repeatedli
implic
mscl
shown
neuroprotect
effect
number
neurodegen
diseas
control
level
peroxid
lipid
coincid
glial
activ
mous
model
enceph
previou
proteom
studi
show
increas
level
apolipoprotein
patient
clinic
isol
syndrom
demyelin
indic
abund
level
protein
highest
mscl
patient
time
first
exacerb
anoth
potenti
interest
protein
found
differenti
elev
comparison
mscl
type
control
ryanodin
receptor
receptor
involv
mainten
calciumequilibrium
brain
tissu
releas
toxic
level
posit
charg
calcium
ion
may
due
deleteri
effect
excitotox
repres
key
mechan
axon
degener
disord
mscl
conclus
csf
peptid
profil
control
sampl
differ
mscl
type
unexpectedli
protein
relat
immun
respons
show
highest
fold
increas
abund
mscl
type
compar
control
even
though
csf
peptid
profil
measur
maldifticr
pp
mscl
rr
mscl
quit
similar
still
differ
could
observ
notabl
regard
molecul
confirm
immunoassay
protein
vitamin
dbind
protein
author
contribut
